Medicines Co. (MDCO) Sinks to Lows Following Inclisiran ORION -1 Phase 2 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
The Medicines Company (MDCO) Additional Phase 2 Data Confirms Market Potential - Guggenheim
November 15, 2016 2:08 PM ESTGuggenheim analyst Louise Chen weighed in on The Medicines Company (NASDAQ: MDCO) following additional data on inclisiran, which according to the analyst, confirms the market potential.
Chen commented, "MDCO (BUY, $26.46) presented more detailed Phase 2 ORION-1 data for Inclisiran (ALN-PCSsc) at AHA after reporting positive top-line... More
Medicines Co. (MDCO) Recovers; Evercore ISI's Raffat Says Data 'Looks Very Consistent and Durable'
November 15, 2016 1:10 PM ESTMedicines Co. (NASDAQ: MDCO) has recovered sharply off intra-day lows as Ph 2 PCSk9 data presented at AHA. Shares are currently down 2.8% after trading down 8% earlier.
Evercore ISI's Umer Raffat said the data "looks very consistent and durable through day 180 (pts getting single... More
Alnylam Pharma (ALNY), Medicines Company (MDCO) Announce Positive Day 90, Prelin. Day 180 Data for Inclisiran Phase 2 Patients
November 15, 2016 11:46 AM ESTThe Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced positive results from the analysis of Day 90 data for 497 patients, as well as analysis of preliminary Day 180 data for 189 patients, enrolled in the ORION -1 Phase 2 study of inclisiran. Data from ORION-1 were presented today in a... More
